BioSpace News Archive

AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today the Company will be making a presentation at the Biotech Showcase conference in San Francisco at the Hilton San Francisco Union Square Hotel

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today provided a corporate update including preliminary net revenue for 2019, the status of Catalyst’s clinical development programs and other corporate matters

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th at 8:30 a.m. PST.

Cigna’s Health Coaching, Case Management Specialists and Expanded Behavioral Health Offerings improve clinical outcomes and drive affordability for customers, employers and partners

Daiichi Sankyo Company, Limited announced that ENHERTU®, a HER2 directed antibody drug conjugate, is now available by prescription in the U.S.

AllianceRx Walgreens Prime, one of the largest specialty and home delivery pharmacies in the U.S., is pleased to include Trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), a new breakthrough therapy for cystic fibrosis (CF), among other specialty medications available through its pharmacy.

In December 2019, Representatives Ron Kind (D-WI) and Michael Burgess, M.D. (R-TX) along with Anna Eshoo (D-CA), Jason Smith (R-MO), Donald McEachin (D-VA), and Jaime Herrera Beutler (R-WA) introduced H.R. 5534, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019.

A study by Millennium Health published in JAMA Network Open reports that since 2016, rates of positive definitive urine drug test (UDT) results have increased significantly by 42.44% for methamphetamine and 75.46% for fentanyl.

ivWatch announced three new additions to its executive management team with the appointments of Teresa Blevins as Chief Financial Officer, Erin Wendell as Chief Marketing Officer and Paul Stoddard as Vice President of Sales.

Current users were more likely to say they felt migraine controlled their lives, they could no longer participate in hobbies